Neoadjuvant ipilimumab-nivolumab superior to adjuvant nivolumab

被引：0
|
作者：
Sidaway, Peter
机构：
[1] Nature Reviews Clinical Oncology,
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2024年 / 21卷 / 08期
关键词：
D O I：
10.1038/s41571-024-00916-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：566 / 566
页数：1
相关论文
共 50 条
  • [21] Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in locally advanced or oligometastatic melanoma: Preliminary results
    Cocorocchio, E.
    Pala, L.
    Nezi, L.
    Manzo, T.
    Mazzarella, L.
    Fiorenza, L.
    Gandini, S.
    Conforti, F.
    Mazzarol, G.
    Queirolo, P.
    Pennacchioli, E.
    Orsolini, G. M.
    Fierro, M. T.
    Ribero, S.
    Senetta, R.
    Fava, P.
    Picciotto, F.
    Caliendo, V.
    Quaglino, P.
    Ferrucci, P. F.
    ANNALS OF ONCOLOGY, 2020, 31 : S765 - S766
  • [22] Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma
    Kielkowski, Brooke
    Mansour, Diana
    Ebbert, Brooke
    Seago, Kelsea
    Wen, Sijin
    Li, Hang
    Barrett, Christine
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [23] Ipilimumab/nivolumab/nivolumab/prednisoneVarious toxicities: case report
    Reactions Weekly, 2023, 1963 (1) : 305 - 305
  • [24] Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome.
    Cocorocchio, Emilia
    Gandini, Sara
    Nezi, Luigi
    Manzo, Teresa
    Mazzarella, Luca
    Barberis, Massimo
    Lanfrancone, Luisa
    Pala, Laura
    Conforti, Fabio
    Pennacchioli, Elisabetta
    Orsolini, Gianmarco
    Fierro, Maria Teresa
    Quaglino, Pietro
    Senetta, Rebecca
    Caliendo, Virginia
    Stucchi, Concetta Riviello Sara
    Macandog, Angeli Dominique
    Frige, Gianmaria
    Ferrucci, Pier Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable stage III melanoma
    Lowe, M.
    Yushak, M. L.
    Olson, B.
    Mokhtari, A.
    Harutyunyan, A.
    Delman, K.
    Parker, D.
    Evans, E.
    Fisher, T.
    Lesinski, G.
    Kudchadkar, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S906 - S906
  • [26] Neoadjuvant Pepinemab in Combination with Nivolumab and/ or Ipilimumab in Resectable Stage III Melanoma
    Lowe, Michael C.
    Olson, Brian
    Yushak, Melinda
    Mallow, Crystal
    Reilly, Christine
    Hammons, Jacklyn
    Burns, Brian
    Mokhtari, Ali
    Parker, Doug
    Fisher, Terry
    Evans, Elizabeth
    Paulos, Chrystal
    Delman, Keith
    Lesinski, Gregory
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S5 - S5
  • [27] Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome
    Cocorocchio, E.
    Nezi, L.
    Gandini, S.
    Manzo, T.
    Mazzarella, L.
    Lotti, F.
    Pala, L.
    Gnagnarella, P.
    Conforti, F.
    Pennacchioli, E.
    Fierro, M. T.
    Ribero, S.
    Senetta, R.
    Picciotto, F.
    Caliendo, V.
    Quaglino, P.
    Mazzarol, G.
    Orsolini, G. M.
    Prestianni, P.
    Ferrucci, P. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S889 - S890
  • [28] Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Chapman, Paul B.
    Jayaprakasam, Vetri Sudar
    Panageas, Katherine S.
    Callahan, Margaret
    Postow, Michael A.
    Shoushtari, Alexander N.
    Wolchok, Jedd D.
    Warner, Allison Betof
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
  • [29] Neoadjuvant Nivolumab and Ipilimumab for Nonmetastatic Renal Cell Carcinoma with Tumor Thrombus
    Master, Viraj A.
    Schmeusser, Benjamin N.
    Osunkoya, Adeboye O.
    Palacios, Arnold R.
    Midenberg, Eric
    Yantorni, Lauren
    Ogan, Kenneth
    Bilen, Mehmet A.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 50 - 55
  • [30] Clinical Decision-Making About Neoadjuvant Nivolumab Plus Ipilimumab
    Gil-Sierra, Manuel David
    Sanchez-Hidalgo, Marina
    Alarcon de la Lastra-Romero, Catalina
    JAMA ONCOLOGY, 2021, 7 (02) : 309 - 309
12345